GITNUXSOFTWARE REVIEW
Science & ResearchTop 10 Best Process Development Services of 2026
Editorial comparison of process development services for biopharma teams, covering fit, tradeoffs, and providers like Lonza.
How we ranked these tools
Vendors set the topic, but our editors set the inclusion criteria and the evaluation framework before research starts.
AI search agents find sources, extract figures with provenance, and aggregate written reviews. They also transcribe video reviews and podcasts.
Framework: Features 40% · Ease 30% · Value 30%
Gitnux may earn a commission through links on this page. This does not influence our reviews. Editorial policy
Thermo Fisher Scientific Patheon is the best fit for biopharma teams needing end-to-end process development through transfer because its transfer-ready batch record package links characterization learnings to manufacturing execution controls for the next scale stage, while Evotec is a strong alternative when you want tightly connected process characterization and analytical development tied to measurable performance shifts across development stages.
Editor’s top 3 picks
Three quick recommendations before you dive into the full comparison below — each one leads on a different dimension.
Thermo Fisher Scientific Patheon
Transfer-ready batch record package that connects characterization learnings to manufacturing execution controls for the next scale stage.
Best for: Fits when biopharma teams need end-to-end process development-to-transfer execution with cGMP-aligned documentation.
Evotec
Editor pickStudy plans that connect critical process parameters to measurable performance shifts across development stages.
Best for: Fits when biopharma teams need tightly linked process characterization, analytical development, and transfer-ready documentation.
Lonza
Editor pickProgram delivery that links design space studies and risk assessment outputs into tech transfer packages for manufacturing handoff.
Best for: Fits when regulated development teams need integrated execution support across characterization, methods, and technology transfer.
Comparison Table
Thermo Fisher Scientific Patheon
enterprise_vendorContract development and manufacturing organization offering CSV services for manufacturing systems.
Transfer-ready batch record package that connects characterization learnings to manufacturing execution controls for the next scale stage.
Thermo Fisher Scientific Patheon is most relevant for teams that want a single accountable partner across process development artifacts, including experimental planning, process characterization inputs, and transfer-ready documentation. The engagement fit is strongest when work must connect laboratory findings to pilot-scale operational settings and manufacturing execution constraints, since execution evidence is built around batch-centric records rather than slide-level summaries. Governance depth is reinforced through documented procedures for deviations and change handling that align with cGMP expectations around process consistency.
A notable tradeoff is that program teams must actively manage integration points, since successful outcomes depend on timely provision of starting materials, target product quality expectations, and internal acceptance criteria for the transfer package. A common usage situation is a midstream scale-up decision where a development process must be refined into a transfer dossier with testable parameters and a practical control strategy for the first commercial-relevant runs.
- +Batch record and SOP-aligned execution artifacts support predictable tech transfer handoffs
- +Scale-up work is tied to practical process understanding rather than experiments alone
- +Analytical development packages connect results to characterization and acceptance criteria
- +Documented deviation and change handling supports audit-ready continuity of process knowledge
- –Requires strong client-side input on acceptance criteria and materials for fast iteration
- –API and automation surfaces are not the main interaction layer for day-to-day execution
- –Transfer readiness depends on aligning internal QbD expectations early
CMC and process development teams
Need structured tech transfer package
Faster manufacturing onboarding
Scale-up program owners
Refine design space for pilot runs
Reduced scale-up surprises
Show 2 more scenarios
Quality and regulatory strategy teams
Prepare documentation for validation planning
Cleaner validation readiness
Development outputs are packaged to support control strategy inputs and dossier-ready process understanding.
Analytical method teams
Develop methods tied to process characterization
More actionable test results
Analytical development activities are structured to generate data that map to acceptance criteria and characterization goals.
Best for: Fits when biopharma teams need end-to-end process development-to-transfer execution with cGMP-aligned documentation.
Evotec
specialistProcess development services spanning discovery through commercial manufacturing.
Study plans that connect critical process parameters to measurable performance shifts across development stages.
Evotec delivers process development services tied to pharmaceutical discovery-to-development workflows, with a focus on executing experimentally grounded development plans. The distinct strength is end-to-end support that connects formulation and analytical work with process characterization, so development decisions reflect measurable outputs.
Teams receive structured study plans that map critical process parameters to performance impacts across lab and pilot-relevant conditions. Engagements are typically governed through project documentation deliverables and decision gates aimed at preparing later stage technology transfer and validation packages.
- +Ties experimental process characterization to practical development decisions
- +Supports analytical method development aligned to process and product outcomes
- +Uses structured documentation outputs for downstream technology transfer
- +Handles multi-stage work spanning feasibility through scale-up planning
- –Deliverables and timelines depend on scope clarity and sample availability
- –Documentation depth can increase administrative overhead for distributed teams
- –Some specialized characterization work may require external lab scheduling
- –Integrated automation coverage varies by site and project requirements
Biologics process development teams
Transfer upstream, downstream, analytics
Manufacturing progression documentation
Biology teams without assay capacity
Build assays for screening studies
Screening-ready methods
Show 2 more scenarios
Candidate development portfolio teams
Run gated characterization experiments
Milestone-based selection evidence
Plans cross-functional experiments tied to progression evidence for candidate selection decisions.
Translational precision medicine teams
Link biomarkers to discovery-to-development decisions
Patient decision-ready findings
Integrates biomarker analytics and mechanistic biology into experiments that inform patient-relevant choices.
Best for: Fits when biopharma teams need tightly linked process characterization, analytical development, and transfer-ready documentation.
Lonza
enterprise_vendorIntegrated pharma process development and manufacturing services from clinical to commercial scale.
Program delivery that links design space studies and risk assessment outputs into tech transfer packages for manufacturing handoff.
Lonza delivers process development services spanning formulation development, analytical method development, and tech transfer toward clinical and commercial manufacturing. Teams get end-to-end support that connects process characterization, design space exploration, and risk assessment outputs into documentation for regulatory-facing workflows.
The key distinction is deep operational capability across biologics and small-molecule programs, with scale-up and scale-down guidance geared to manufacturing execution needs. Delivery quality shows up in how work products map to execution artifacts like batch record inputs and process development reports.
- +Cross-domain process development coverage from formulation to tech transfer
- +Analytical method development aligned to characterization and regulatory documentation needs
- +Practical scale-up planning that ties experiments to manufacturing execution constraints
- +Clear risk assessment outputs used to shape control strategy decisions
- –Engagement requires strong internal coordination to keep inputs and change control aligned
- –Process characterization depth can vary by program maturity and available internal samples
- –Automation and API surfaces are not a primary delivery mechanism
- –Document turnaround cadence depends on site scheduling and analytical workload
Biologics process development teams
Support mammalian cell line development
Cell line aligned plan
Pharma CMC and program teams
Coordinate development and fill-finish
Coordinated handoff package
Show 2 more scenarios
Pharmaceutical analytical development teams
Characterize therapeutic proteins comprehensively
Cross-method analytical evidence
Runs mass spectrometry, structural, biophysical, and stability studies for development decision support.
Industrial enzyme development teams
Optimize engineered enzymes for process use
Process-ready enzyme candidates
Improves enzyme activity and stability to meet application-specific process and manufacturing constraints.
Best for: Fits when regulated development teams need integrated execution support across characterization, methods, and technology transfer.
Samsung Biologics
enterprise_vendorLarge-scale biologics process development and CDMO services.
Technology transfer execution that links experiment outcomes to batch record translation and scale-ready process documentation.
Samsung Biologics supports end-to-end process development workflows that start with defining process parameters and mapping them to product quality behavior through structured characterization studies. The engagement model typically covers process characterization, risk assessment inputs for a control strategy, and execution of experiments designed to inform design space and scale transitions. The quality of delivery tends to track manufacturing realities such as equipment capability, mixing and mass transfer effects, and feasibility of batch record translation into standard operating procedure style workflows.
- +Practical scale transition work tied to manufacturing equipment constraints
- +Structured characterization outputs that support process understanding and control strategy drafting
- +Analytical method development support aligned with process sampling workflows
- +Transfer-focused documentation designed to feed batch record and SOP authoring
- –Requires strong alignment on upstream materials and testing logistics
- –Documentation depth can lag if decision gates are delayed internally
- –Speed can depend on facility scheduling for pilot experiments
- –Limited transparency into experiment planning details without frequent review touchpoints
CMC and process development teams
Plan characterization studies for parameter-to-quality links
Defensible process understanding
Regulatory submission owners
Assemble transfer evidence for dossier-ready documentation
Cohesive submission package
Show 1 more scenario
Analytical development leads
Align sampling and method work with process changes
Comparable measurement datasets
Analytical method development supports process experiments without breaking sample comparability.
Best for: Fits when teams need manufacturing-relevant process development evidence and transfer-ready documentation for submission timelines.
WuXi AppTec
enterprise_vendorProcess development services for small molecules, biologics, and cell therapies.
Integrated CMC execution that links process characterization outputs to analytical validation evidence and transfer-ready documentation packages.
WuXi AppTec supports process characterization work that feeds into design space definitions, and it connects those outputs to batch execution planning and process control documentation. The provider also runs analytical method development and method validation activities that are needed to generate release and stability evidence for process change decisions. Teams get a single program interface spanning upstream or chemical synthesis steps, downstream or formulation work where relevant, and the supporting analytical workstreams.
- +Converges process work and analytical evidence into one development storyline
- +Structured tech transfer artifacts support controlled scale-up and documentation
- +Works across multiple modalities with consistent CMC execution discipline
- +Handles method validation work needed for release and stability readouts
- –Requires disciplined sponsor governance to manage cross-workstream change control
- –Project timelines depend on analytical turnaround and sample availability
Regulated biotech sponsors
Generate process control documentation
Implementation-ready control package
CMC teams managing change control
Validate methods for stability evidence
Validated release evidence
Show 2 more scenarios
Pharmaceutical development sponsors
Coordinate multi-stage drug development
Fewer cross-team handoffs
Orchestrates program work that reduces handoffs across discovery, testing, clinical, and manufacturing streams.
Research organizations without capacity
Outsource lab operations with records
Traceable study records
Manages assay execution, sample logistics, documentation, and analytical deliverables across stages.
Best for: Fits when a sponsor needs coordinated process and analytical execution for transfer and validation readiness.
Almac Group
specialistProcess development and scale-up services for API and drug product manufacturing.
Single engagement teams align analytical method readiness with process scale-up evidence for transfer decisions.
Almac Group serves process development teams that need end-to-end chemistry, manufacturing, and analytical execution with scientific staff embedded in regulated workflows. Its core capabilities span process characterization, analytical method development and validation, and support for technology transfer into pilot and commercial manufacturing contexts.
- +Cross-functional delivery links process work to analytical method development timelines
- +Documented, regulated workflow orientation supports consistent process development reporting
- +Strong analytical execution reduces rework during method validation and transfer
- +Experienced teams support risk assessment outputs used in control strategy discussions
- –Change requests can require more governance time than internal teams expect
- –Deep involvement is often needed to map client requirements into execution plans
- –Analytical scope coverage can lag when projects demand broad multi-matrix testing
- –Integration with internal lab systems may rely on structured manual handoffs
Pharmaceutical process teams
Support scale-up and transfer
Scale-up transfer documentation
Clinical bioanalytical teams
Develop and validate protein biomarker assays
Validated biomarker methods
Show 2 more scenarios
Drug development assay teams
Execute bioassays and potency testing
Study-ready bioanalytical data
Outsources cell-based and biochemical assay development with documented potency results.
GxP laboratory operations teams
Manage request-to-results workflows
Traceable protocol-driven workflows
Configures study-driven lab processes with audit trails and instrument data capture controls.
Best for: Fits when drug teams need integrated process and analytical delivery for regulated technology transfer milestones.
Quotient Sciences
specialistProcess development and clinical trial manufacturing services for drug products.
Integrated development-to-reporting workflow that turns characterization findings into a structured process development report used for later regulatory steps.
Quotient Sciences delivers process development services that connect experimental work to regulatory-ready documentation for chemistry, manufacturing, and controls. Its core capability centers on designing and executing process development activities for biologics and related modalities, then translating outcomes into control strategy artifacts used in submissions.
- +Regulated documentation workflow supports consistent handoff to submission teams
- +Process characterization execution tied to critical process parameters and controls
- +Analytical method development support reduces cross-team alignment gaps
- +Operational traceability strengthens audit readiness for development activities
- –Integration depth can be limited if internal systems require custom data plumbing
- –Turnaround depends on experimental throughput and method readiness constraints
- –Complex design space work may require tighter study design governance
- –Change control discipline is needed to prevent downstream rework
CMC leads for biologics
Support biologics process characterization for filings
Faster submission-ready control strategy
Analytical development teams
Develop methods for process monitoring
Defined monitoring methods and criteria
Show 2 more scenarios
Tech transfer managers
Plan tech transfer and validation execution
Clear handoff to validation
Produces execution planning that connects process work to downstream validation and manufacturing readiness.
Regulatory quality systems owners
Maintain traceable regulated documentation
Audit-ready experimental documentation
Runs process development activities in quality workflows that preserve traceability through authoring.
Best for: Fits when teams need end-to-end process development that outputs submission-ready development reporting artifacts.
Aragen Life Sciences
specialistProcess development and contract research services for pharmaceutical and biotech clients.
Process development report deliverables that connect experimental observations to control strategy draft decision logic.
Aragen Life Sciences delivers process development services for biologics and small molecules, with a track record centered on experimental execution, characterization, and scale-up planning. The engagement model typically maps method and process experiments into a documented process development report, linking observed behavior to design space decisions and control strategy drafts.
- +Strong execution of process characterization experiments tied to documented decision points
- +Clear linkage between risk assessment outputs and draft control strategy elements
- +Manufacturing-facing documentation artifacts support later tech transfer work
- +Experienced coordination of analytical method development alongside process experiments
- –Governance for cross-study change control depends on client process maturity
- –Automation and API integration depth is not a productized interface layer
- –Turnaround for iterative DoE cycles is sensitive to inbound analytical readiness
- –Limited evidence of self-serve dashboards for experiment status and audit trails
Process development scientists
Runs method experiments and links design space
Clear experiment-to-decision traceability
Tech transfer managers
Produces execution-ready tech transfer documentation
Handoffs ready for execution
Show 2 more scenarios
Analytical chemistry leads
Coordinates analytics during development runs
Coordinated analytics and reporting
Aligns analytics planning with experimental execution so results support control strategy development.
Manufacturing readiness teams
Plans scale-up with practical batch records
Reduced scale-up execution risk
Maps observed behavior to scale-up planning so manufacturing teams can execute with fewer gaps.
Best for: Fits when teams need hands-on process development execution plus manufacturing-oriented documentation.
Cambrex
specialistAPI process development and scale-up services for pharmaceutical manufacturers.
Integrated development-to-transfer documentation that ties experiments, analytical results, and control strategy into a single tech transfer-ready package.
Cambrex runs process development and technical transfer work for small-molecule and biologics manufacturing, with deliverables designed for regulated change control. Strength is the ability to convert lab-scale studies into validated, scalable manufacturing steps that feed directly into process development reports and tech transfer packages.
- +Regulated tech transfer packages that map process steps to documentation expectations
- +Analytical method development support tied to impurity profiling and specification setting
- +Experiment planning and risk assessment artifacts usable for control strategy narratives
- +Experience running scale-up work that reduces downstream validation surprises
- –Governance-heavy handoffs can slow iteration when requirements change midstream
- –Automation and API integration for internal data systems is not a primary delivery surface
- –Large, cross-study programs can require tighter planning than smaller proof-of-concept efforts
- –Some advanced modeling artifacts depend on the agreed workflow and scope boundaries
Regulatory CMC leads
Supports defensible control strategy filings
Reduced CMC justification gaps
Process development scientists
Scales lab studies into validated steps
Validated scale-up parameters
Show 2 more scenarios
Quality systems managers
Implements risk-informed experimentation and controls
More defensible in-process controls
Delivers impurity profiling and risk-informed experiments that strengthen process robustness.
Analytical method owners
Develops methods for transfer packages
Transfer-ready analytical methods
Pairs analytical method development with tech transfer deliverables for consistent release readiness.
Best for: Fits when regulated process development teams need execution across analytical work, scale-up, and validation support.
Curia
specialistProcess development and manufacturing services for small molecules and biologics.
Experiment-to-decision reporting that maps executed runs to process parameter changes and downstream handoff artifacts.
Curia provides process development services with a biotech and pharmaceutical delivery focus, emphasizing technically detailed characterization work and documentation outputs used in regulated development programs. Teams typically use Curia for process design, optimization, and technical transfer support across development stages that feed into downstream regulatory-ready artifacts.
- +Strong experimental planning and run traceability for development decisions
- +Clear process documentation structure for cross-team reviews
- +Practical scale-up and technology transfer support for manufacturing handoffs
- +Deep domain coverage across development workflows that touch QA deliverables
- –Requires the client to maintain tight inputs, timelines, and review cadence
- –Automation and API surface for data integration is not a primary delivery artifact
- –Turnaround depends on lab execution scheduling and internal review cycles
- –Limited evidence of configurable governance controls for distributed teams
CMC development scientists
Optimize formulation parameters for stability
Regulatory-ready stability strategy
Process development leaders
Transfer process to contract manufacturing
Higher transfer acceptance
Show 2 more scenarios
Regulatory documentation teams
Assemble technical reports from experiments
Faster dossier drafting
Curia supplies controlled characterization outputs that map assumptions to runs and decisions.
Analytical method owners
Characterize delivery system performance
Improved method suitability
Curia supports technically detailed characterization work tied to development stage artifacts.
Best for: Fits when regulated process development needs experiment-driven decisions and audit-ready documentation handoffs.
Conclusion
After evaluating 10 process development, Thermo Fisher Scientific Patheon stands out as our overall top pick — it scored highest across our combined criteria of features, ease of use, and value, which is why it sits at #1 in the rankings above.
Use the comparison table and detailed reviews above to validate the fit against your own requirements before committing to a tool.
Frequently Asked Questions About Process Development
How do process development teams typically integrate vendor outputs with internal documentation systems?
Which providers handle analytics-to-control strategy traceability best for regulated submissions?
How does SSO and RBAC typically show up in process development project onboarding for these providers?
What data migration work is usually required when moving existing experiments into a new vendor program workflow?
Which provider fit helps when a process development team needs extensibility for changing experimental plans mid-project?
What breaks if a team cannot align internal equipment capability assumptions early?
How do vendors translate design space studies into batch record and SOP-style execution artifacts?
When should teams choose a vendor that runs both analytical development and method validation alongside process development?
How can clients establish admin controls over experiment runs and decision gates during a multi-workstream engagement?
Tools reviewed
Primary sources checked during evaluation.
Referenced in the comparison table and product reviews above.
How to Choose the Right Process Development
Options differ most in how you run process development work end-to-end: whether you can capture lineage and evidence in the templates you use, and whether the workflow supports controlled iterations without losing decisions. Look for coverage in the process iteration log, evidence management, and change governance, not just report generation.
Process iteration workflow
Why it matters
A strong process iteration workflow matters because process development work is iterative, and teams need to keep experiments, results, and rework in the right order. If the workflow is weak, people will copy work into spreadsheets and you lose traceability across versions.
How to check
Ask for a sample workflow: create one run, link inputs and outputs, then revise and show the prior version remains accessible. Confirm whether the tool enforces a sequence (draft → review → complete) and records who changed what and when.
Evidence and decision lineage
Why it matters
Evidence and decision lineage matters because teams must justify why a process choice was made based on outputs they can reproduce later. Without lineage, reviewers can’t see which results supported which decisions during process development.
How to check
During a demo, pick a decision point and show where it links to the underlying artifacts (run outputs, notes, attachments). Try deleting or editing an artifact and ask what happens to the links and audit trail.
Change governance for process artifacts
Why it matters
Change governance for process artifacts matters because process development often alters parameters, methods, and operating boundaries as learning accumulates. Governance that is too light causes inconsistent versions to circulate across teams.
How to check
Ask how the tool handles a changed parameter or template: can you require review, enforce versioning, and prevent “quiet overwrites”? Request to see an example audit log entry and the current vs previous view.
Collaborative review cycles
Why it matters
Collaborative review cycles matter because process development usually involves cross-functional review (e.g., lab, engineering, QA). If the tool can’t route review, comment, and sign-off around the right artifacts, the iteration pace slows and rework grows.
How to check
In a demo, initiate a review on one artifact and add comments from two roles. Check whether comments are tied to specific sections/attachments, whether resolution status is tracked, and whether you can export the review record.
Automation and API for workflows
Why it matters
Automation and API for workflows matters because process development teams often move data between instruments, notebooks, ELN/LIMS, and internal systems. A documented automation surface reduces manual transcription and keeps evidence consistent.
How to check
Ask for examples of provisioning new projects, creating run records, and linking artifacts via API or automation jobs. Request a sandbox or test environment and try a small import that creates the same lineage as the UI does.
Red flags
- Workflow supports drafts but doesn’t preserve previous versions with clear linkage to outcomes.
- Evidence links break after edits or deletions, leaving decisions unsupported.
- Reviews and sign-offs float at the project level instead of attaching to specific artifacts.
Fit by situation
- If your team runs frequent parameter iterations with multiple reviewers, prioritize Process iteration workflow.
- If your main pain is reconstructing why choices were made, prioritize Evidence and decision lineage.
- If you need to ingest results from other systems with minimal retyping, prioritize Automation and API for workflows.
Funding and competing interests
This study was co-funded by several of the vendors assessed in it. No single vendor funded it. Funders could propose the market studied.
They had no role in selecting vendors, setting or weighting criteria, analysing data or drawing conclusions, and they received the same factual-accuracy check as every other vendor assessed.
Market definition, inclusion rules and criteria weights were fixed by an editor before research began and did not change afterwards. Editorial process →
- Service review · 2026 · Science ResearchMethod Development
- Service review · 2026 · Business Process OutsourcingProcess Consulting
- Service review · 2026 · Biotechnology PharmaceuticalsBiological Process Development
- Review · 2026 · Digital Transformation In IndustryDevelopment Process Software
- Review · 2026 · Data Science AnalyticsData Processing Software
Keep exploring
Comparing two specific tools?
Software Alternatives
See head-to-head software comparisons with feature breakdowns, pricing, and our recommendation for each use case.
Explore software alternatives→In this category
Science & Research alternatives
See side-by-side comparisons of science & research tools and pick the right one for your stack.
Compare science & research tools→